Please enable JavaScript.
Coggle requires JavaScript to display documents.
Biotech主流 (CAR-T (2017.8 FDA announced "Novartis's Kymriah",…
Biotech主流
CAR-T
- 2017.8 FDA announced "Novartis's Kymriah", (ALL)
- 2017.8 FDA announced "Kite Pharma's Yescarta", (DLBCL)
美國： Novartis, Kite, Juno, Bluebird, Adaptimmune, Obsidian Therapeutics
-
-
原理：讓T-Cell能有效辨別標的（CD19, 22抗原）細胞
-
PD-1
原理：PD-1為抑制T-Cell之protein, 因此療法為anti- PD-1, PD-L1 or PD-L2
Organoid
- 和傳統plate上的單一細胞相比，類器官的形成更能反映真實情況。
-
-
-
-